Enobosarm Has Antitumor Activity in ER-Positive, HER2-Negative Advanced Breast Cancer
At 24 weeks, 32 and 29 percent of patients in the 9-mg and 18-mg groups had clinical benefit
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.